Topic: Novavax

The FDA has authorized a new version of the Novavax vaccine targeting the JN1 strain, which has become the dominant seasonal variant. Health officials compare the current state of COVID-19 to the common cold, noting that the virus continues to mutate but at a more stable rate than the flu. Additionally, a new Moderna vaccine named "M Nex Spike" has received approval as the pharmaceutical industry continues its booster strategy.

The show addresses the influx of notes from military personnel being forced to take COVID-19 vaccines just years before retirement, with many opting for Novavax as a non-mRNA alternative. Christopher Meacham is knighted as "Sir Mechamus Prime" after a decade of listening and using the show's encouragement to launch his own sci-fi podcast, "The Smugglers Log."

The FDA granted emergency use authorization to the Novavax COVID-19 vaccine for adults, providing a protein-based alternative to mRNA options. While some individuals have waited for this specific technology to avoid mRNA, the hosts express skepticism regarding the company's history and the timing of the release.

The FDA is evaluating the Novavax vaccine following reports of myocarditis and pericarditis in other countries. Unlike the Pfizer and Moderna vaccines, Novavax is a non-mRNA option. Additionally, an Israeli study is mentioned linking COVID-19 vaccines to a 25% increase in cardiac arrests among young people.

The UK Parliament confirmed that participants in the Novavax clinical trials will receive vaccine passports regardless of whether they received the active vaccine or a placebo. In a separate media event, a Newsmax anchor erroneously claimed that COVID-19 vaccines are not FDA-approved for senior citizens during an interview with Senator Rand Paul. The segment also highlighted the frequent verbal confusion between the terms "virus" and "vaccine" in broadcast media.

The South African COVID-19 variant has been detected in Maryland and South Carolina, appearing to spread through community transmission. Clinical trials for the Novavax vaccine showed a drop in efficacy from 90% in the UK to 49% in South Africa due to this variant. Dr. Fauci suggests that vaccines will need to be "nimble" and may require regular booster shots to address ongoing mutations.

The hosts analyze the stock performance of biotech companies like Moderna and Gilead Sciences following mentions by Larry Kudlow. They clarify that Gilead's drug, Remdesivir, is an antiviral treatment originally developed for Ebola, not a vaccine. They emphasize that a viable vaccine is likely at least 18 months away despite market hype.